Liraglutide

What it is (in plain language)
- It's a medicine that mimics a natural hormone that your gut releases after eating. It tells the pancreas to produce the right amount of insulin and, at the same time, signals the brain that you are satisfied. Unlike newer versions, this one is administered daily.

Why do you appear online so much
- Known commercially as Victoza or Saxenda, it was the first major 'slimming peptide' to go viral. It is the reference standard for controlling type 2 diabetes and obesity before the arrival of Semaglutide.

How it is framed today (pragmatic view)
- 1) Evidence: Approved by regulatory agencies (FDA/EMA) with decades of safety data. 2) Objective: Sustained weight loss and glycaemic control. 3) Risk: Nausea and pancreatitis (in rare cases); requires strict medical monitoring.

How to use this form
- See the 'Dosage' section to understand the importance of progressive titration to avoid gastric discomfort.

- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Fat Loss
- Route: Injectable
- Tags: Injectable|Fat Loss|Approved
- Half-life: ~13 Hours
- Start: Hours
- Duration: 24 hours

- Mechanism (high level)
GLP-1 receptor agonist. Delays gastric emptying and signals satiety to the brain. Increases glucose-dependent insulin secretion.

- Evidence (what the literature covers)
RESEARCH RANGE (Approved, Non-prescriptive):
Saxenda/Victoza.
Level of Evidence: A.

- Safety and harm-reduction (non-prescriptive)
Risks: Frequent nausea.
Risk of pancreatitis (rare).
C-cell thyroid tumours (rodents).
Interactions: Insulin/Sulfonylureas.

- References (anchors)
- Pi-Sunyer, X. (2015) - Liraglutide in Weight Management (SCALE) - https://doi.org/10.1056/NEJMoa1411892
- PubMed:26132939

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.